SLC7A11 and type 2 diabetes mellitus: This was primarily demonstrated by the high expression of SLC7A11 and GPX4 in the T2DM + MaR1 group and the low expression of SLC7A11 and GPX4 in the T2DM + MaR1 + siNRF2 group, suggesting that MaR1′s ability to improve osteoblast proliferation and osteogenic differentiation depends on the inhibition of ferroptosis (Figure 3H,I).